Raritan: Johnson & Johnson has announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration (FDA) for TAR-200 for the treatment of patients ...

Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational drug-device combination to treat certain patients with non-muscle invasive ...

Alboslani detailed this research in her presentation "X-ray echoes from Sgr A* reveal the 3D structure of molecular clouds in the Galactic Center" at the 245th meeting of the American Astronomical ...

This is an RNA molecule generated in the lab that the team first presented in 2023. The researchers from the Institute of Organic Chemistry were able to determine the 3D structure of SAMURI using ...

Objective: To investigate the optimal cut-off value of immunohistochemical marker Ki67 as a prognostic factor to predict the recurrence of non-muscle invasive bladder urothelial carcinoma (NMIBUC).

The team believes that the structure was in use until the 8th century BCE, the middle of the period when the Kings of Judah ruled. A scarab seal from the 8th century BCE uncovered during the ...

Decentralized social network organization Mastodon said Monday that it is planning to create a new nonprofit organization in Europe and hand over ownership of entities responsible for key Mastodon ...

“LNPs have achieved significant success for non-viral gene delivery, particularly in COVID-19 vaccines, but not much has been known about how the LNP structure affects bioactivity,” said HighField CEO ...

Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor sasanlimab in patients with BCG-naïve, high-risk, non-muscle invasive ...

"Patients with BCG-naïve high-risk non-muscle invasive bladder cancer have high rates of recurrence and progression," said Neal Shore, M.D., FACS, Medical Director for the Carolina Urologic ...